David H Henry

Summary

Country: USA

Publications

  1. ncbi Guidelines and recommendations for the management of anaemia in patients with lymphoid malignancies
    David H Henry
    Joan Karnell Cancer Center, Pennsylvania Hospital, Philadelphia, Pennsylvania 19106, USA
    Drugs 67:175-94. 2007
  2. ncbi Hematologic outcomes and blood utilization in cancer patients with chemotherapy-induced anemia (CIA) pre- and post-national coverage determination (NCD): results from a multicenter chart review
    David H Henry
    Joan Karnell Cancer Center, Pennsylvania Hospital, Philadelphia, PA 19106, USA
    Support Care Cancer 20:2089-96. 2012
  3. ncbi Optimizing the treatment of anemia in cancer patients. The role of a new erythropoietic agent
    David H Henry
    Joan Karnell Cancer Center, Pennsylvania Hospital, Philadelphia 19106, USA
    Oncology (Williston Park) 16:9-12. 2002
  4. ncbi Symptoms and treatment burden associated with cancer treatment: results from a cross-sectional national survey in the U.S
    David H Henry
    Joan Karnell Cancer Center, Pennsylvania Hospital, 230 W Washington Square, Philadelphia, PA, 19106, USA
    Support Care Cancer 16:791-801. 2008
  5. ncbi Intravenous ferric gluconate significantly improves response to epoetin alfa versus oral iron or no iron in anemic patients with cancer receiving chemotherapy
    David H Henry
    Joan Karnell Cancer Center, Pennsylvania Hospital, 230 West Washington Square, Philadelphia, PA 19106, USA
    Oncologist 12:231-42. 2007
  6. ncbi Natural history of anemia associated with interferon/ribavirin therapy for patients with HIV/HCV coinfection
    David H Henry
    Joan Karnell Cancer Center, Pennsylvania Hospital, Philadelphia, PA 19106, USA
    AIDS Res Hum Retroviruses 23:1-9. 2007
  7. ncbi The role of intravenous iron in cancer-related anemia
    David H Henry
    Department of Medicine, Pennsylvania Hospital, Philadelphia, Pennsylvania 19106, USA
    Oncology (Williston Park) 20:21-4. 2006
  8. ncbi Epoetin alfa for the treatment of cancer- and chemotherapy-related anaemia: product review and update
    David H Henry
    Joan Karnell Cancer Center, Pennsylvania Hospital, 230 West Washington Square, 2nd Floor, Philadelphia, PA 19106, USA
    Expert Opin Pharmacother 6:295-310. 2005
  9. ncbi The evolving role of epoetin alfa in cancer therapy
    David H Henry
    Joan Karnell Cancer Center, Pennsylvania Hospital, Philadelphia, Pennsylvania 19106, USA
    Oncologist 9:97-107. 2004
  10. ncbi Epoetin alfa for treatment of anemia in HIV-infected patients: past, present, and future
    David H Henry
    Department of Oncology, Hematology, Pennsylvania Hospital, Philadelphia, PA 19106, USA
    J Acquir Immune Defic Syndr 37:1221-7. 2004

Detail Information

Publications28

  1. ncbi Guidelines and recommendations for the management of anaemia in patients with lymphoid malignancies
    David H Henry
    Joan Karnell Cancer Center, Pennsylvania Hospital, Philadelphia, Pennsylvania 19106, USA
    Drugs 67:175-94. 2007
    ..Clearly, an update on the definition, identification and optimal management of anaemia in patients with lymphoid malignancies is warranted...
  2. ncbi Hematologic outcomes and blood utilization in cancer patients with chemotherapy-induced anemia (CIA) pre- and post-national coverage determination (NCD): results from a multicenter chart review
    David H Henry
    Joan Karnell Cancer Center, Pennsylvania Hospital, Philadelphia, PA 19106, USA
    Support Care Cancer 20:2089-96. 2012
    ..The primary objective of this study was to compare transfusion rates in patients with CIA with lung, breast, or colorectal cancer before and after the NCD...
  3. ncbi Optimizing the treatment of anemia in cancer patients. The role of a new erythropoietic agent
    David H Henry
    Joan Karnell Cancer Center, Pennsylvania Hospital, Philadelphia 19106, USA
    Oncology (Williston Park) 16:9-12. 2002
    ..The articles in this supplement describe the basic scientific research and clinical development of darbepoetin alfa--another safe, effective, and approved treatment for chemotherapy-induced anemia...
  4. ncbi Symptoms and treatment burden associated with cancer treatment: results from a cross-sectional national survey in the U.S
    David H Henry
    Joan Karnell Cancer Center, Pennsylvania Hospital, 230 W Washington Square, Philadelphia, PA, 19106, USA
    Support Care Cancer 16:791-801. 2008
    ..To examine the prevalence of chemotherapy-or radiotherapy-associated side effects and related treatment burden, and correlates of fatigue and missed work days among cancer patients...
  5. ncbi Intravenous ferric gluconate significantly improves response to epoetin alfa versus oral iron or no iron in anemic patients with cancer receiving chemotherapy
    David H Henry
    Joan Karnell Cancer Center, Pennsylvania Hospital, 230 West Washington Square, Philadelphia, PA 19106, USA
    Oncologist 12:231-42. 2007
    ..To evaluate the safety and efficacy of intravenous (IV) sodium ferric gluconate complex (FG), oral ferrous sulfate, or no iron to increase hemoglobin (Hb) in anemic cancer patients receiving chemotherapy and epoetin alfa...
  6. ncbi Natural history of anemia associated with interferon/ribavirin therapy for patients with HIV/HCV coinfection
    David H Henry
    Joan Karnell Cancer Center, Pennsylvania Hospital, Philadelphia, PA 19106, USA
    AIDS Res Hum Retroviruses 23:1-9. 2007
    ..sEPO and reticulocyte increases were blunted in response to anemia; Hb levels did not return to baseline values and anemia was a frequent reason for discontinuing the study...
  7. ncbi The role of intravenous iron in cancer-related anemia
    David H Henry
    Department of Medicine, Pennsylvania Hospital, Philadelphia, Pennsylvania 19106, USA
    Oncology (Williston Park) 20:21-4. 2006
    ..v. iron supplementation in improving the hematopoietic responses in these patients...
  8. ncbi Epoetin alfa for the treatment of cancer- and chemotherapy-related anaemia: product review and update
    David H Henry
    Joan Karnell Cancer Center, Pennsylvania Hospital, 230 West Washington Square, 2nd Floor, Philadelphia, PA 19106, USA
    Expert Opin Pharmacother 6:295-310. 2005
    ..Areas of recent and ongoing investigation with epoetin alfa are also covered in this review...
  9. ncbi The evolving role of epoetin alfa in cancer therapy
    David H Henry
    Joan Karnell Cancer Center, Pennsylvania Hospital, Philadelphia, Pennsylvania 19106, USA
    Oncologist 9:97-107. 2004
    ..Thus, the role of epoetin alfa is likely to expand in the cancer setting in the coming years...
  10. ncbi Epoetin alfa for treatment of anemia in HIV-infected patients: past, present, and future
    David H Henry
    Department of Oncology, Hematology, Pennsylvania Hospital, Philadelphia, PA 19106, USA
    J Acquir Immune Defic Syndr 37:1221-7. 2004
    ..Current and future research will further clarify the role of epoetin alfa in the clinical management of the HIV-infected population...
  11. ncbi Epoetin alfa. Clinical evolution of a pleiotropic cytokine
    David H Henry
    Pennsylvania Hospital, Joan Karnell Cancer Center, Philadelphia, PA 19106, USA
    Arch Intern Med 164:262-76. 2004
    ..The therapeutic potential of epoetin alfa appears yet to be fully realized...
  12. ncbi Thrombocytosis and venous thromboembolism in cancer patients with chemotherapy induced anemia may be related to ESA induced iron restricted erythropoiesis and reversed by administration of IV iron
    David H Henry
    Department of Medicine, Pennsylvania Hospital, University of Pennsylvania, Philadelphia, Pennsylvania 19106, USA
    Am J Hematol 87:308-10. 2012
    ..Our study suggests that ESA associated VTE in CIA patients may be, in part, related to the thrombocytosis of ESA induced iron restricted erythropoiesis and may be countered by IV iron...
  13. ncbi Randomized, open-label comparison of epoetin alfa extended dosing (80 000 U Q2W) vs weekly dosing (40 000 U QW) in patients with chemotherapy-induced anemia
    David H Henry
    Joan Karnell Cancer Center, Pennsylvania Hospital, Philadelphia, PA, USA
    Curr Med Res Opin 22:1403-13. 2006
    ..CONCLUSIONS: Extended dosing (80 000 U Q2W) and once-weekly dosing (40 000 U QW) of EPO provided comparable safety and efficacy for chemotherapy-induced anemia...
  14. ncbi Blood management in total joint arthroplasty
    Hari R Bezwada
    Balderston Orthopaedics, Pennsylvania Hospital, 800 Spruce St, Philadelphia, PA 19107, USA
    Am J Orthop (Belle Mead NJ) 35:458-64. 2006
    ..This article reviews these techniques as well as the consequences of perioperative anemia. Problems associated with blood transfusions are also outlined...
  15. ncbi Parenteral iron therapy in cancer-associated anemia
    David H Henry
    Joan Karnell Cancer Center at Pennsylvania Hospital, Philadelphia, PA 19106, USA
    Hematology Am Soc Hematol Educ Program 2010:351-6. 2010
    ....
  16. ncbi Preoperative use of recombinant human erythropoietin before total joint arthroplasty
    Hari P Bezwada
    Pennsylvania Hospital, Philadelphia, 19107, USA
    J Bone Joint Surg Am 85:1795-800. 2003
    ..The purpose of this study was to evaluate the efficacy of erythropoietin in combination with, and compared with, preoperative autologous donation for reducing allogeneic blood requirements for total joint arthroplasty...
  17. ncbi Randomized, double-blind study of denosumab versus zoledronic acid in the treatment of bone metastases in patients with advanced cancer (excluding breast and prostate cancer) or multiple myeloma
    David H Henry
    Joan Karnell Cancer Center, Philadelphia, PA 19106, USA
    J Clin Oncol 29:1125-32. 2011
    ....
  18. ncbi Phase 1/2 trial of BMS-275291 in patients with human immunodeficiency virus-related Kaposi sarcoma: a multicenter trial of the AIDS Malignancy Consortium
    Brett T Brinker
    Division of Hematology Oncology, Department of Medicine, Feinberg School of Medicine, Northwestern University and the Robert H Lurie Comprehensive Cancer Center of Northwestern University, Chicago, IL, USA
    Cancer 112:1083-8. 2008
    ....
  19. ncbi Thrombosis with erythropoietic stimulating agents-does iron-deficient erythropoiesis play a role?
    Naomi V Dahl
    Semin Dial 21:210-1. 2008
    ..The major anemia trials of ESAs have not reported platelet data, but should examine the relationship of platelet count, iron deficiency, IV iron administration, and cardiovascular events in greater detail...
  20. ncbi Guidelines for the use of epoetin in cancer patients: a much-needed step forward in standardizing anemia treatment
    David H Henry
    Blood 102:2697-8. 2003
  21. ncbi Increased importance of intravenous iron in chemotherapy-induced anemia
    Michael Auerbach
    J Clin Oncol 25:2145-6. 2007
  22. ncbi Efficacy and safety analysis of epoetin alfa in patients with small-cell lung cancer: a randomized, double-blind, placebo-controlled trial
    Thomas Grote
    Forsyth Regional Cancer Center, Winston Salem, NC 27103, USA
    J Clin Oncol 23:9377-86. 2005
    ..This randomized, double-blind, placebo-controlled trial (N93-004) evaluated the effects of epoetin alfa on tumor response to chemotherapy and survival in patients with small-cell lung cancer (SCLC)...
  23. ncbi Autologous stem-cell transplantation can be performed safely without the use of blood-product support
    Karen K Ballen
    Division of Hematology Oncology, Massachusetts General Hospital, 100 Blossom St, Cox 640, Boston, MA 02114, USA
    J Clin Oncol 22:4087-94. 2004
    ..Most transplants require RBC and platelet support. We report the ability to perform autologous transplantation without blood-product support...
  24. ncbi Clinical benefits and risks associated with epoetin and darbepoetin in patients with chemotherapy-induced anemia: a systematic review of the literature
    Susan D Ross
    MetaWorks, Inc, Medford, Massachusetts 02155, USA
    Clin Ther 28:801-31. 2006
    ..Evidence-based guidelines and systematic reviews of the management of CIA do not yet include all currently approved ESPs or all of the clinically relevant benefits and risks of ESPs...
  25. ncbi T-1249 retains potent antiretroviral activity in patients who had experienced virological failure while on an enfuvirtide-containing treatment regimen
    Jacob P Lalezari
    Quest Clinical Research, San Francisco, California, USA
    J Infect Dis 191:1155-63. 2005
    ..CONCLUSIONS: These results indicate that FIs constitute an expanding class of antiretroviral agents with the potential to be sequenced...
  26. ncbi High-molecular weight iron dextran: a wolf in sheep's clothing?
    George M Rodgers
    J Am Soc Nephrol 19:833-4. 2008
  27. ncbi Phase II trial of infusional cyclophosphamide, doxorubicin, and etoposide in patients with HIV-associated non-Hodgkin's lymphoma: an Eastern Cooperative Oncology Group Trial (E1494)
    Joseph A Sparano
    Albert Einstein Cancer Center and Montefiore Medical Center, Weiler Division, 1825 Eastchester Road 2 South, Rm 47 48, Bronx, NY 10461, USA
    J Clin Oncol 22:1491-500. 2004
    ..To determine the effectiveness of an infusional chemotherapy regimen in patients with HIV-associated lymphoma treated before and after the use of highly active antiretroviral therapy (HAART) in routine clinical practice...
  28. ncbi Comparative outcomes study of metformin intervention versus conventional approach the COSMIC Approach Study
    Dennis R Cryer
    Bristol Myers Squibb Company, 777 Scudders Mill Rd, Plainsboro, NJ 08536, USA
    Diabetes Care 28:539-43. 2005
    ..Metformin was approved by the Food and Drug Administration in 1995 subject to the conduct of a randomized trial to evaluate the risk of lactic acidosis or other serious adverse events (SAEs) with this agent, under usual care conditions...